Financial Performance - In 2025, the company achieved a revenue of CNY 31.603 billion, representing a year-on-year growth of 14.43% [3] - The net profit attributable to shareholders was CNY 3.421 billion, with a growth of 1.58% [3] - The net cash flow from operating activities reached CNY 5.513 billion, increasing by 25.23% compared to the previous year [3] - The overall gross margin for 2025 was 54.03%, up by 2.17 percentage points year-on-year [4] Business Segments - The CHC (Consumer Health Care) segment generated revenue of CNY 15.111 billion, a decline of 14.67% [3] - The prescription drug segment saw revenue of CNY 12.094 billion, a significant increase of 101.38% [3] R&D and Innovation - R&D investment for 2025 was CNY 1.734 billion, focusing on cardiovascular, oncology, digestive metabolism, and respiratory treatments [5] - The company achieved multiple project collaborations and received several drug registration certificates, enhancing its product portfolio [5][6] Market Strategy - The company aims to maintain its leadership in the respiratory and skin care markets while expanding its product offerings [7] - The prescription drug business is guided by clinical value, with a focus on innovation and collaboration [8] Shareholder Returns - The proposed dividend for 2025 is CNY 5.90 per 10 shares, totaling approximately CNY 1.73 billion, which is 50.59% of the net profit [8] - Cumulative dividends since the company's listing have exceeded CNY 10 billion [25] Future Outlook - The company anticipates that the pharmaceutical industry will continue to face challenges in 2026, but expects to exceed the average industry growth rate [9] - The strategic focus for the "15th Five-Year Plan" includes enhancing R&D capabilities and leveraging AI for digital transformation [11][29] Market Trends - The company recognizes the ongoing shift towards digitalization in retail, with online sales expected to exceed 10% of total sales by 2025 [17] - The aging population trend is driving the need for health products, aligning with the company's strategic focus on health care [29]